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Background: Adults with single ventricle congenital heart disease are at risk for significant adverse events, including arrhythmias, 
thromboembolism, and heart failure. Reliable measures for risk stratification can aid in the treatment of adults with single ventricle physiology. 
This study sought to evaluate the usefulness of percent maximum predicted heartrate (%HRmax) and maximum oxygen consumption (VO2max) in 
predicting adverse events in this patient population.
Methods: All patients with single ventricle congenital heart disease and available cardiopulmonary exercise testing data were included in 
this single center retrospective review. Adverse clinical outcomes evaluated were supraventricular tachycardia (SVT) requiring hospitalization or 
electrophysiology study, ventricular tachycardia (VT), congestive heart failure (CHF), thromboembolic events, heart or heart/lung transplantation, and 
death.
Results: Forty-five (19 male) patients were included in this study. Mean age was 32.7 +/- 9 years (Range 20-55 years). All patients had been 
previously palliated, including 19 (42%) classical Fontans and 19 (42%) total cavopulmonary connections. Twenty-six (58%) patients suffered 
adverse clinical events, including SVT, VT, CHF, thromboembolic events, and heart transplantation. There were no deaths. Mean %HRmax was 67.4 
+/- 13.8 % in patients suffering adverse events, compared to 83.4 +/- 8.9 % in patients without adverse events (p = < 0.0001). Mean %HRmax in 
patients with SVT was 69.79 +/- 11.7% (n=18), 54.87 +/- 2.23% (n=3) in patients with VT, 61.15 +/- 13.2% (n=6) in patients with CHF, and 76.63 
+/- 10.7% (n=6) in patients with thromboembolism (p=.032). VO2max was also a useful predictor of adverse events, with a mean VO2max of 16.4 
+/- 6 ml/kg/min in patients with adverse outcomes, compared to 22.8 +/- 6.9 ml/kg/min in those without adverse events (p = 0.003).
Conclusions: %HRmax and VO2max may be used to help identify adults with single ventricle physiology at increased risk for adverse clinical 
outcomes.
